NasdaqCM - Nasdaq Real Time Price USD

Sunshine Biopharma, Inc. (SBFM)

0.8074 -0.1226 (-13.18%)
At close: April 25 at 4:00 PM EDT
0.8199 +0.01 (+1.55%)
Pre-Market: 4:26 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
24,092.7870
24,092.7870
4,345.6030
228.4260
71.4100
Cost of Revenue
15,753.6160
15,753.6160
2,649.0280
117.8300
25.8470
Gross Profit
8,339.1710
8,339.1710
1,696.5750
110.5960
45.5630
Operating Expense
13,124.4700
13,124.4700
10,370.6060
2,550.7300
622.4370
Operating Income
-4,785.2990
-4,785.2990
-8,674.0310
-2,440.1340
-576.8740
Net Non Operating Interest Income Expense
674.6660
674.6660
479.2380
-328.8180
-168.1050
Other Income Expense
-0.2450
-0.2450
-18,316.3430
-9,667.4950
-2,039.1120
Pretax Income
-4,110.8780
-4,110.8780
-26,511.1360
-12,436.4470
-2,784.0910
Tax Provision
395.1660
395.1660
233.3040
--
--
Net Income Common Stockholders
-4,506.0440
-4,506.0440
-26,744.4400
-12,436.4470
-2,784.0910
Diluted NI Available to Com Stockholders
-4,506.0440
-4,506.0440
-26,744.4400
-12,436.4470
-2,784.0910
Basic EPS
-0.19
--
-1.76
-4.76
-2.73
Diluted EPS
-0.19
--
-1.76
-4.76
-2.73
Basic Average Shares
24,331.9080
--
15,180.8680
2,612.0610
1,020.4820
Diluted Average Shares
24,331.9080
--
15,180.8680
2,612.0610
1,020.4820
Total Operating Income as Reported
-4,785.2990
-4,785.2990
-27,000.7500
-2,440.1340
-576.8740
Total Expenses
28,878.0860
28,878.0860
13,019.6340
2,668.5600
648.2840
Net Income from Continuing & Discontinued Operation
-4,506.0440
-4,506.0440
-26,744.4400
-12,436.4470
-2,784.0910
Normalized Income
-4,505.8970
-4,505.8970
-13,228.8105
-2,768.9520
-741.9790
Interest Income
811.9740
811.9740
518.6500
--
--
Interest Expense
137.3080
137.3080
39.4120
328.8180
168.1050
Net Interest Income
674.6660
674.6660
479.2380
-328.8180
-168.1050
EBIT
-3,973.5700
-3,973.5700
-26,471.7240
-12,107.6290
-2,615.9860
EBITDA
-3,824.4230
-3,824.4230
-26,446.5610
-12,094.8880
-2,601.9200
Reconciled Cost of Revenue
15,753.6160
15,753.6160
2,649.0280
117.8300
25.8470
Reconciled Depreciation
149.1470
149.1470
25.1630
12.7410
14.0660
Net Income from Continuing Operation Net Minority Interest
-4,506.0440
-4,506.0440
-26,744.4400
-12,436.4470
-2,784.0910
Total Unusual Items Excluding Goodwill
-0.2450
-0.2450
-18,316.3430
-9,667.4950
-2,042.1120
Total Unusual Items
-0.2450
-0.2450
-18,316.3430
-9,667.4950
-2,042.1120
Normalized EBITDA
-3,824.1780
-3,824.1780
-8,130.2180
-2,427.3930
-559.8080
Tax Rate for Calcs
0.0004
0.0004
0.0003
--
--
Tax Effect of Unusual Items
-0.0980
-0.0980
-4,800.7135
--
--
12/31/2020 - 2/15/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SXTC China SXT Pharmaceuticals, Inc.
1.0300
-3.74%
 
PTPI Petros Pharmaceuticals, Inc.
0.6399
+0.87%
 
AKAN Akanda Corp.
0.0915
+2.01%
 
AQST Aquestive Therapeutics, Inc.
3.9300
+0.77%
 
CPHI China Pharma Holdings, Inc.
0.3260
+3.49%
 
OPTN OptiNose, Inc.
0.9050
-2.19%
 
EVO Evotec SE
5.10
-2.49%
 
CGC Canopy Growth Corporation
8.70
-3.01%
 
ACB Aurora Cannabis Inc.
6.71
-6.81%
 
ESPR Esperion Therapeutics, Inc.
1.9900
-6.57%